Variation in use of menopausal hormone treatment on risk of health outcomes

Table 1 Distribution of outcomes and variation of use of menopausal hormone therapy in study cohort

	No. of women
	Never-users		Ever-users
No. of events during 14 yr follow-up (% in group)
Coronary artery disease	33	(11.5%)	29	(14.3%)
Stroke	23	(8.0%)	19	(9.4%)
Peripheral arteria disease	10	(3.5%)	19	(9.4%)
Breast cancer	20	(6.9%)	12	(5.9%)
Timing of initiation of therapy from onset of menopause
“Early start” ( ≤ 3 yr)	-		162	(80.2%)
“Late start” (> 3 yr)	-		40	(19.8%)
Type of regimen
Oestrogen-only	-		30	(14.8%)
Oestrogen + progestogen	-		168	(83.2%)
Tibolone	-		4
Combination of treatment strategy
Early start plus oestrogen-only	-		20	(9.9%)
Early start plus oestrogen + progestogen	-		140	(69.3%)
Late start plus oestrogen-only	-		10	(4.9%)
Late start plus oestrogen + progestogen	-		28	(13.9%)
Other			4
Age of patient when treatment started
20-39 yr	-		17	(8.4%)
40-49 yr	-		85	(42.0%)
50-59 yr	-		82	(40.6%)
60-69 yr	-		18	(8.9%)
70-79 yr	-		17	(8.4%)
Age of patient when treatment stopped
20-39 yr	-		0
40-49 yr	-		20	(9.9%)
50-59 yr	-		85	(42.1%)
60-69 yr	-		69	(34.1%)
70-79 yr	-		28	(13.9%)
Duration of use (yr)
< 1	-		15	(7.4%)
1-5	-		67	(33.2%)
6-10	-		37	(18.3%)
11-15	-		45	(22.3%)
16-20	-		19	(9.4%)
21-25	-		11	(5.4%)
> 25	-		7	(3.4%)
Total No. of women	287		202